89Zr-TLX250

89Zr-TLX250 · Telix Pharmaceuticals (Innovations) Pty Limited

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for 89Zr-TLX250, covering 2024-05-17 to 2025-12-30. Get the full timeline:

Most recent: Clinical Trial Update: Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer [Phase 2]

See pricing